Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
about
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cellsCo-targeting of convergent nucleotide biosynthetic pathways for leukemia eradicationInhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines.ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice.PET probes for distinct metabolic pathways have different cell specificities during immune responses in miceFast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging systemEfficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugsDeoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistanceThe reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasisStructure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe.Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene.Noninvasive prediction of tumor responses to gemcitabine using positron emission tomographyArmed and targeted measles virus for chemovirotherapy of pancreatic cancer.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Lipid-based drug carriers for prodrugs to enhance drug delivery.Evaluation of the Genisys4, a bench-top preclinical PET scanner5',6'-nucleoside phosphonate analogues architecture: synthesis and comparative evaluation towards metabolic enzymes.Liposomes- and ethosomes-associated distamycins: a comparative study.RNAi depletion of deoxycytidine and deoxyguanosine kinase in human leukemic CEM cells.Liposomes and micellar dispersions for delivery of benzoheterocyclic derivatives of distamycin A.Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling.Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
P2860
Q24653228-2A8C3B77-BB39-4750-8EA6-0F176A25AFE7Q27681888-862C7CCD-8701-450F-8FEF-43CBB7B68636Q31028788-7F726B54-BBE9-48B5-A9A4-B7945BFDDFE1Q33510686-A69552C9-0FE3-49B8-A507-1BC6A1481F0CQ33881305-DCA3E70D-4081-4B8C-9D63-325D3D4ABD67Q33931793-487C93FF-6237-4E93-88CF-607248EBB54CQ33997393-0B62ED86-0BCC-4116-BFA6-96FA9CD7DFB4Q34015533-77A820C2-C6D4-488A-ABB9-909AEB28B66EQ34656357-2F69782A-7E55-47C8-9D98-AA1BC1371F1EQ35643725-0046FEB3-B160-4D46-AB13-E1F7AA2196CAQ35994964-07EC26D7-293E-4B11-8B7C-F68AFC01A52BQ36201693-61CA707F-1DE4-40DE-A440-E53E66692CF5Q36583196-60FBE01A-48DB-4AF8-AEBE-3E8A690C1D2CQ37085729-1663F985-B426-4F59-8B2F-17C98600AEC1Q37557813-77FEBAFC-76AC-4428-B08C-9E67E663FAEEQ38125770-E05C8EDE-5F74-4482-85A9-C24AB328B720Q38255590-BD2B9A81-EE28-4467-9CF5-10F06964C352Q39158593-73147595-142A-463A-A8BF-2294F37F8D6FQ39543558-1EF1E0F0-E19B-49CD-883B-BC4CBA91F386Q39766948-65793B21-5865-4FA5-9167-A410E69BC6CDQ39965255-FEBF8C76-DB28-4D72-B756-1361672E407BQ40208202-BA5AA68B-BECC-47D1-93CD-96FD90EE20E1Q40215768-8EA51780-2E4D-45E1-9B17-C7248AC1BFD1Q42206991-D0615EC1-871A-444C-8F7E-835F17341E0EQ49387560-95D443FA-96BA-4879-8188-C181B0D07C1CQ52931150-9E9FE836-AFC6-4402-9DDE-72EBF467BB44Q57175017-FC536B0D-A08C-4525-A548-27173F9D7EBD
P2860
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Characterization of a gemcitab ...... e by a mononucleotide prodrug.
@en
type
label
Characterization of a gemcitab ...... e by a mononucleotide prodrug.
@en
prefLabel
Characterization of a gemcitab ...... e by a mononucleotide prodrug.
@en
P2093
P50
P1476
Characterization of a gemcitab ...... ce by a mononucleotide prodrug
@en
P2093
Carlos M Galmarini
Christian Perigaud
Emeline Cros
Marie-Hélène Gouy
Suzanne Peyrottes
P304
P356
10.1158/1078-0432.CCR-04-0506
P407
P577
2004-08-01T00:00:00Z